ZCUBE
9.6.2020 08:02:10 CEST | Business Wire | Press release
Zcube, Zambon Research Venture, has launched the fourth edition of Open Accelerator , the international acceleration programme dedicated to startups in the Life Sciences, which seeks to identify and accelerate the best solutions that will shape the future of health. The 2020 Call, focused on digital solutions, is running until the 20th of July. Candidates can apply on the website www.openaccelerator.it
Open Accelerator is looking for innovative, high-tech projects and startups leveraging digital technologies to improve patients’ lives . The best proposals will take part in the acceleration program with the possibility of receiving a seed investment of up to € 100,000 per project.
The 2020 Call for Solutions is preferably targeted at the therapeutic areas of the Central Nervous System and Respiratory, with a particular focus on the 4 technological macro areas: Digital Prevention, Monitoring and Therapeutics; Digital Diagnostics; Virtual Health; Clinical Trials Digitalization.
This year, in an attempt to transform the COVID-19 emergency into a growth opportunity for the healthcare system, ZCube is also presenting the Special Challenge concerning new ways of interaction among healthcare professionals, Industry and the community.
“Open Accelerator is continuing with conviction into its fourth edition, reaffirming its commitment to supporting young startups, helping to transform promising projects into concrete solutions for patients” – comments Elena Zambon, President of Zambon Spa and creator of the accelerator programme – “Digital solutions have never been such a vital support for patients and caregivers as they have at this time. We have direct experience of this through ParkinsonCare, our telenursing service with a human touch. That is why we have decided to dedicate the 2020 Call to digital initiatives. We are convinced that they will be increasingly important in tackling the challenges that lie ahead in terms of health and the system's sustainability. This programme is yet another way in which we are pursuing with conviction our commitment to improving patients' lives, integrating cure and care with a multidisciplinary approach”.
After the closure of the Call, on the 20th of July, the Open Accelerator team in collaboration with a panel of experts will select the startups which between October and November will participate in the intensive 4-week acceleration programme , consisting of tailored online and onsite sessions held in the OpenZone scientific campus just outside Milan .
By taking part in the Open Accelerator programme, the startups will have access to a vast international network of entrepreneurs, scientists, investors, Venture capitalists and Life Sciences professionals. At the end of the programme the most promising projects will be awarded a seed investment of up to € 100,000 . Finally, any possible synergies with the companies of the Zambon Group will be assessed.
“Open Accelerator 2020 Call is one of a kind both- for its focus on digital health technologies and for its pragmatic approach, strongly focused on identifying concrete proposals for delivering solutions to healthcare needs ” - says Fabrizio Conicella, General Manager and Board Member of OpenZone and Zcube - “It is only through the active engagement of existing and prospective partnerships that we will be able to maximize the potential of the proposals we receive and select with a clear objective: to offer to the market innovative solutions that currently don't exist ”.
The initiative also leverages the support of several partners, including Deloitte, Unicredit Start Lab, Premio Marzotto, IQVIA Biotech, Italian Angels for Biotech, Portolano & Cavallo, Bird&Bird, Innogest, Evoleen, HUMA, NINA Capital, and Lifeseeder. Discussions are currently underway with other potential Italian and international partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005658/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 16:19:00 CEST | Press release
Milestone reinforces the Citation Latitude’s position as the world’s best-selling midsize business jet. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircr
OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 16:00:00 CEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release
Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release
Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be
From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release
Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
